Fornaro, Lorenzo http://orcid.org/0000-0002-0187-5904
Lonardi, Sara
Catanese, Silvia
Nappo, Floriana
Pietrantonio, Filippo
Pellino, Antonio
Angerilli, Valentina
Signorini, Francesca
Salani, Francesca
Murgioni, Sabina
Neculaescu, Ioana Ancuta
Bruno, Rossella
Vivaldi, Caterina
Ricagno, Gianmarco
Masi, Gianluca
Bergamo, Francesca
Ugolini, Clara
Fassan, Matteo
Funding for this research was provided by:
Istituto Oncologico Veneto (BIOV19LOUPAK)
Ministero della Salute (NET-2016–02363853)
Associazione Italiana per la Ricerca sul Cancro (22759, IG 23624)
Article History
Received: 3 April 2023
Accepted: 12 June 2023
First Online: 29 June 2023
Declarations
:
: LF reports personal honoraria as invited speaker from Incyte, Bristol Myers Squibb, Lilly; research funding (to Institution) from MSD, Bristol Myers Squibb, AstraZeneca, Incyte, BeiGene, Astellas, Daiichi Sankyo, Roche; participation in advisory board for MSD, AstraZeneca, Incyte, Taiho, Servier, Daiichi Sankyo, Lilly. SL reports research funding (to Institution) from Amgen, Astellas, Astra-Zeneca, Bayer, Bristol-Myers Squibb, Daichii Sankyo, Hutchinson, Incyte, Merck Serono, Mirati, MSD, Pfizer, Roche, Servier; personal honoraria as invited speaker from Amgen, Bristol-Myers Squibb, Incyte, GSK, Lilly, Merck Serono, MSD, Pierre-Fabre, Roche, Servier; participation in advisory board for Amgen, Astra Zeneca, Bristol-Myers Squibb, Daiichi-Sankyo, Incyte, Lilly, Merck Serono, MSD, Servier. FP reports personal fees from Amgen, Merck-Serono, Pierre-Fabre, Servier, Bayer, MSD, Bristol Myers Squibb, Lilly, AstraZeneca, Astellas, Organon, and research grants from AstraZeneca, Agenus, Incyte and Bristol Myers Squibb. MF has been involved in consulting/advisory roles in Astellas Pharma, Pierre Fabre, MSD, AstraZeneca, Janssen, GlaxoSmithKline, Amgen, Novartis and Roche, and received research funding from Astellas Pharma, QED Therapeutics, Diaceutics and Macrophage Pharma. All other authors declare that they have no conflict of interest.
Free to read: This content has been made available to all.